Home › Trials › NCT06645886

Investigating KQB198 for treating advanced blood cancers

A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of KQB198 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hematologic Malignancies

Phase 1 Interventional Kumquat Biosciences Inc. · NCT06645886

This study is testing a new drug called KQB198 to see if it can safely help adults with advanced blood cancers, either on its own or with other cancer treatments.

Quick facts

PhasePhase 1
Study typeInterventional
Enrollment122 (estimated)
Ages18 Years and up
SexAll
SponsorKumquat Biosciences Inc. Industry-sponsored
Drugs / interventionsdasatinib
Locations21 sites (San Francisco, California and 20 other locations)
Trial IDNCT06645886 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to evaluate the safety and efficacy of KQB198, both as a standalone treatment and in combination with other anti-cancer drugs, for adults with advanced hematologic malignancies. Participants will take KQB198 daily and will be monitored through regular clinic visits to assess the drug's effects on tumor size and its safety profile. The study will also investigate how KQB198 is processed in the body. The trial includes specific cohorts based on prior treatments and responses to existing therapies.

Who should consider this trial

Good fit: Ideal candidates include adults with Ph+ CML in chronic phase who have previously been treated with multiple TKIs and are not responding to those treatments.

Not a fit: Patients with CML in accelerated or blast phase or those who have had prior therapy with a similar mechanism to KQB198 may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with advanced hematologic malignancies who have limited alternatives.

How similar studies have performed: Other studies have shown promise with similar approaches, but the specific use of KQB198 is novel.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Adequate organ function

Part 1 and Part 2, Cohort B Participants Only:

• Ph+ CML in chronic phase who have been previously treated with at least 2 different tyrosine kinase inhibitors (TKIs) and are relapsed from or intolerant to those TKIs and ineligible for alternative therapeutic options likely to produce clinical benefit as determined by the investigator.

Part 2, Cohort A Participants Only:

• Participants with Ph+ CML in chronic phase who are on dasatinib prior to study entry and have a warning or failure to dasatinib as determined by the investigator per ELN 2020 guidelines

Exclusion Criteria:

* CML in accelerated or blast phase
* Prior therapy with a similar mechanism of action to KQB198
* History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow
* History of interstitial lung disease
* Cardiac abnormalities

Where this trial is running

San Francisco, California and 20 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Hematologic MalignanciesAdultCMLdasatinib
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.